Compare CMMB & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMMB | OM |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 85.0M |
| IPO Year | N/A | 2020 |
| Metric | CMMB | OM |
|---|---|---|
| Price | $1.62 | $3.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $26.50 | $16.00 |
| AVG Volume (30 Days) | 105.9K | ★ 518.6K |
| Earning Date | 11-20-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,069,000.00 |
| Revenue This Year | N/A | $5.77 |
| Revenue Next Year | N/A | $9.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.65 |
| 52 Week Low | $1.60 | $3.10 |
| 52 Week High | $9.84 | $25.35 |
| Indicator | CMMB | OM |
|---|---|---|
| Relative Strength Index (RSI) | 26.53 | 30.84 |
| Support Level | $1.60 | $3.10 |
| Resistance Level | $1.83 | $3.83 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 10.09 | 42.01 |
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.